A higher prevalence of epigenetic inactivation of tumor suppressor genes has been reported in cancer cell line populations compared to primary cancer populations. Cancer-related genes are commonly methylated in cancer cell lines but it is not known the extent to which tumor suppressor genes may be arti®cially methylated in vitro. We therefore examined 10 pancreatic cancer cell lines and corresponding primary tumors for aberrant DNA methylation of promoter CpG islands of eight genes and seven CpG islands. Using methylation-speci®c PCR (MSP), methylation was not detected at any of the 15 CpG islands in 15 normal pancreata or in an immortalized normal pancreatic duct epithelial (HPDE) cell line. Of 150 loci examined, 49 loci were methylated in both primary carcinomas and their corresponding cell lines, 95 loci were not methylated in either cell lines or their corresponding primary carcinomas. There were four loci methylated only in cell lines while another two loci were methylated only in primary carcinomas. Overall, the methylation status of primary carcinomas and their cell lines were concordant in 96% of cases (144 of 150) (J statistic; J=0.92, P50.0001). We conclude that most of the DNA methylation of tumor suppressor genes observed in cancer cell lines is present in the primary carcinomas from which they were derived.
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Keywords: CpG island methylation; pancreatic adenocarcinoma; cell line A higher prevalence of methylation of tumor suppressor gene promoters has been observed in cancer cell lines compared to primary carcinomas (Bachman et al., 1999; Dammann et al., 2000; Herman et al., 1995; Merlo et al., 1995) . Although transcriptional repression by 5' CpG island hypermethylation is an important mechanism of inactivation of tumor suppressor genes (Esteller et al., 2001) , the implication that 5' CpG island methylation may be an in vitro artifact raises uncertainty about the signi®cance of some aberrant methylation events observed in human cancer cell lines. Several hypotheses have been proposed to explain this observation. First, Antequera et al. (1990) have observed that when normal cells are passaged in culture the promoters of several normally nonmethylated genes become silenced by DNA methylation, perhaps because their expression is no longer essential. Second, some genes that may be crucial for successful cell passage appear to undergo methylationinduced silencing during immortalization of normal cells (Foster et al., 1998; Jones et al., 1990) . Third, it has been suggested that subclones within primary cancers with aberrant CpG island methylation may be preferentially selected during cell passage . Fourth, in some primary cancers, low neoplastic cellularity can make it dicult to characterize aberrant DNA methylation . Finally, it is conceivable that cancers with high levels of aberrant CpG methylation could be more likely to become established as cell lines.
To clarify the extent that aberrant DNA methylation in cancer cell lines originates in vitro, we compared the methylation status of 10 pancreatic cancer cell lines and their corresponding primary carcinomas in a panel of 15 CpG islands. The panel included the promoters or 5' regions of p16, hMLH1, retinoic acid receptor b (RARb), thrombospondin-1 (THBS1), tissue inhibitor metalloproteinase-3 (TIMP-3), Cyclin G, Preproenkephalin (ppENK), a T-type calcium channel (CAC-NA1G) and seven CpG islands (MICP20, 23, 33, 36, MINT1, 31 and 32) . Seven of these CpG islands were originally recovered from colorectal (Toyota et al., 1999) and pancreatic cancer cell lines (Ueki et al., 2000 (Ueki et al., , 2001 . These 15 loci have been shown to be frequent targets for aberrant methylation in pancreatic carcinomas and are not normally methylated within the pancreas (Ueki et al., 2000 (Ueki et al., , 2001 . Several of the genes in this panel have tumor suppressive properties. For example, p16 is inactivated in *95% pancreatic adenocarcinomas and in *15% of cases inactivation occurs by aberrant promoter methylation (Schutte et al., 1997) . ppENK is a growth suppressor that we have recently demonstrated to be commonly silenced by methylation in pancreatic adenocarcinoma (Ueki et al., 2001) . RARb has growth suppressive properties and is silenced by methylation in several cancers including lung cancer (Virmani et al., 2000) . In this study, we used methylation speci®c PCR (MSP) to identify methylated DNA templates in primary carcinomas and cell lines (Herman et al., 1996a) .
We obtained primary adenocarcinomas and normal pancreatic tissue from pancreatic resection specimens in The Johns Hopkins Medical Institutions Pathology archive. Ten pancreatic cell lines were established in vitro culture from a primary adenocarcinoma in Dr Jaee's laboratory. An immortal epithelial cell line from normal human pancreatic duct epithelium (HPDE) transfected by the E6 and E7 gene of human papilloma virus 16 (Liu et al., 1998) was kindly provided by Ming-Sound Tsao, Ontario cancer institute, Toronto, Ontario, Canada. Frozen tissues from the same 10 primary pancreatic carcinomas that were passaged as cell lines above were microdissected to obtain greater than 50% of neoplastic cells. Genomic DNA was extracted from cell lines, frozen specimens and normal pancreata using standard methods.
Bisul®te treatment of DNA was carried out for 16 h at 508C on 1 mg of genomic DNA and the methylation status of each gene was determined by MSP as described previously (Herman et al., 1996a) . To acquire optimal speci®city, each primer pair contained four to six CpG sites and high speci®c annealing temperatures were used. Primer sequences and the conditions for PCR are available at our website [http://pathology2.jhu.edu/pancreas/prim0425.htm]. All PCR reactions were performed with positive controls for both unmethylated and methylated alleles, and no DNAloaded control. For p16 we used MSP primers that corresponded to an area of CpG methylation associated with transcriptional repression (Gonzalgo et al., 1998) .
For statistical analysis Youden's J statistic was used. The J statistic gives a measure of agreement beyond what would be expected by chance alone, giving equal weight to concordant methylated and unmethylated loci. If the methylation status of pancreatic cancer cell lines and their corresponding primary adenocarcinomas, the presumptive`gold-standard', were in complete agreement the J statistic would have the value 1. Conversely, if agreement were no better than that which would be expected by chance alone, the J statistic would have the value 0. Proportions were compared using a Z test.
The results for each cell line/primary cancer pair are demonstrated in Figure 1 . Methylation was not detected at any of the 15 CpG islands in 15 normal pancreata or in the HPDF cell line.
Of 150 loci examined, 49 loci were methylated in both cell lines and primary carcinomas, 95 loci were not methylated in either cell lines or primary carcinomas. There were four discordant loci methylated only in cell lines (CACNA1G, MINT1 and 31) while another two discordant loci were methylated only in primary carcinomas (Cyclin G and MICP20). For 10 genes and CpG islands (p16, hMLH1, THBS1, RARb, TIMP-3, ppENK, MICP23, 33, 36 and MINT32), the methylation status of pancreatic cancer cell lines completely matched their corresponding primary pancreatic adenocarcinomas (Figure 1) . Overall, the methylation status of 96% of loci (144 of 150) was concordant between cell lines and primary carcinomas (J statistic; J=0.92, P50.0001).
Case 9 (PL12) had three completely methylated loci (ppENK, MINT1 and MINT32) and three loci that were both unmethylated and methylated (p16, CAC-NA1G and MICP25). The partial methylation of p16 observed in PL12 may re¯ect the CpG dinucleotides targeted in our MSP, as another MSP primer set for p16 harbored complete methylation of p16 and this cell line does not express p16 transcript (data not shown).
Since higher levels of DNA methylation have been described in cancer cell lines compared to primary carcinomas (Bachman et al., 1999; Dammann et al., 2000; Herman et al., 1995; Merlo et al., 1995) , we compared methylation data in the current panel of cell lines with methylation data from a panel of 45 (Ueki et al., 2000) , and found no signi®cant dierence between the two groups (Ueki et al., 2000) (21% vs 15% of eight loci; P=0.18).
The high concordance of CpG island methylation between pancreatic cancer cell lines and their corresponding primary carcinomas suggests that most aberrant DNA methylation observed in pancreatic cancer cell lines is not an`artifact' due to passage of cultured cancer cells. Indeed, none of the 15 CpG islands we analysed were methylated in the HPDE cell line, suggesting that HPDE cells do not need to methylate these CpG islands during passage. Virtually all loci (96%, 95 of 99) not methylated in primary pancreatic carcinomas were also not methylated in their cell lines, suggesting that most CpG islands are protected from de novo methylation even after repeated in vitro passage. Similarly, almost all genes and CpG islands (96%, 49 of 51) methylated in primary adenocarcinomas were also methylated in their cell lines, supporting the hypothesis that selective growth of neoplastic cells can result from aberrant methylation events (in genes such as p16, ppENK, and others) that continue to be inherited during establishment and passage of cell lines Herman et al., 1996b) .
Using MSP, we found that many of the aberrantly methylated loci in the pancreatic cancer cell lines were clonal. For example, the pancreatic cancer cell line Case 3 was clonal with respect to aberrant methylation of nine CpG islands including p16, hMLH1, THBS1, CACNA1G, ppENK. In contrast, we detected both methylated and unmethylated DNA templates of normally unmethylated CpG islands in some pancreatic cancer cell lines highlighting the fact that the mere detection of aberrantly methylated templates of a tumor suppressor gene in a given cancer is not necessarily an indication that aberrant methylation was sucient to fully inactivate that gene. Of course, many methylation events in tumors are clonal as seen when consequences of aberrant methylation (gene inactivation) is readily observable throughout the carcinoma. For example, carcinomas with aberrant methylation of p16 or hMLH1 display loss of expression of either p16 or of hMLH1 along with microsatellite instability throughout the carcinoma Wilentz et al., 1998 Wilentz et al., , 2000 .
Our results support those of Markl et al. (2001) who recently described relatively stable methylation patterns at *200 CCGG loci in four primary bladder carcinomas from two patients and their corresponding cell lines. Most of the methylated CpG loci studied by Markl et al. (2001) were methylated in both normal and cancerous bladder epithelium, whereas we limited our analysis to CpG islands that are methylated in pancreatic adenocarcinomas but not methylated in normal pancreas. Our results can also clarify other notions concerning DNA methylation in cancer cell lines.
In contrast to the lack of in vitro methylation during passage of primary pancreatic carcinomas to their corresponding cell lines, CpG island hypermethylation of tumor suppressor genes and tissue speci®c genes may be crucial for immortalization of normal cells (Antequera et al., 1990; Foster et al., 1998) . Several studies have demonstrated that inactivation of the Rb/ p16 tumor suppressor pathway is required for immortalization of non-cancer cells (Jarrard et al., 1999) . Promoter methylation and transcriptional repression of p16 has been reported after several passages of human mammary epithelial cells (Foster et al., 1998) . We did not observe in vitro methylation of the p16 promoter in a HPDE cell line. This could be explained by the expression of E7 gene in HPDE cells which is known to inactivate Rb, precluding the need to inactivate p16 (Foster et al., 1998) .
Since none of the 15 CpG islands we analysed were methylated in normal pancreas, it is likely that these loci became de novo methylated during pancreatic carcinogenesis. Our results support the notion that de novo methylation and selection of many normally nonmethylated CpG islands of tumor suppressor genes occurs during carcinogenesis and contributes to the cancer phenotype (Esteller et al., 2001) . While it is easy to envisage the aberrant methylation of genes such as p16 and hMLH1 during pancreatic carcinogenesis, and the aberrant methylation of other genes with tumor suppressor functions in other cancers (for example, VHL, RB, E-cadherin, p14, p15 and others) the functional signi®cance of many aberrant methylation events in cancer remain unknown. Although potentially hundreds of hypermethylation events occur during carcinogenesis (Costello et al., 2000) , one can speculate that many aberrant CpG island methylation events may arise from defects in genes that protect CpG islands from aberrant methylation, with only a proportion of such abnormalities creating a selective advantage for an evolving neoplasm.
In conclusion, the similar rate of aberrant DNA methylation between pancreatic carcinomas before and after in vitro passage demonstrates that the vast majority of aberrant CpG island methylation observed in pancreatic cancer cell lines re¯ects alterations that are present in the primary tumors from which they were derived
